
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Blade Air Mobility Inc (BLDE)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: BLDE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $5.83
1 Year Target Price $5.83
4 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.62% | Avg. Invested days 28 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 386.42M USD | Price to earnings Ratio - | 1Y Target Price 5.83 |
Price to earnings Ratio - | 1Y Target Price 5.83 | ||
Volume (30-day avg) 5 | Beta -0.21 | 52 Weeks Range 2.35 - 5.17 | Updated Date 09/16/2025 |
52 Weeks Range 2.35 - 5.17 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -54.97% | Operating Margin (TTM) -42.8% |
Management Effectiveness
Return on Assets (TTM) -11.29% | Return on Equity (TTM) -24.5% |
Valuation
Trailing PE - | Forward PE 138.89 | Enterprise Value 27986112 | Price to Sales(TTM) 5.75 |
Enterprise Value 27986112 | Price to Sales(TTM) 5.75 | ||
Enterprise Value to Revenue 0.99 | Enterprise Value to EBITDA -9.95 | Shares Outstanding 81695600 | Shares Floating 45245150 |
Shares Outstanding 81695600 | Shares Floating 45245150 | ||
Percent Insiders 11.01 | Percent Institutions 75.82 |
Upturn AI SWOT
Blade Air Mobility Inc

Company Overview
History and Background
Blade Air Mobility, Inc. was founded in 2014. It provides short-distance air transportation alternatives to congested ground routes. It went public via a SPAC merger in 2021.
Core Business Areas
- MediMobility Organ Transport: Facilitates the safe and timely transportation of human organs for transplant, partnering with hospitals and transplant centers.
- Blade Airport: Offers scheduled helicopter and fixed-wing flights between airports and urban centers, primarily catering to business travelers and leisure passengers.
- Blade Urban Air Mobility: Provides on-demand helicopter flights within urban areas, connecting various points within a city.
- International UAM: Expands the urban air mobility services globally, including operations in Europe and Canada
Leadership and Structure
Rob Wiesenthal is the CEO. The company has a typical corporate structure with departments focused on operations, technology, finance, and marketing.
Top Products and Market Share
Key Offerings
- MediMobility Organ Transport: Facilitates organ transport. It is difficult to provide an exact number, but Blade is a major provider in this space in the northeast United States. Competitors include traditional medical transportation services and hospital-owned transport solutions.
- Blade Airport: Scheduled helicopter flights between Manhattan and major airports like JFK and Newark. Market share data is not readily available. Competitors include ground transportation services, private car services, and other helicopter services.
- Blade Urban Air Mobility: On-demand helicopter flights within cities like New York. Market share data is not readily available. Competitors include ground transportation and other helicopter charter services.
Market Dynamics
Industry Overview
The urban air mobility (UAM) industry is in its early stages, characterized by technological innovation, regulatory hurdles, and increasing investment. It aims to provide efficient and convenient transportation solutions in congested urban areas.
Positioning
Blade Air Mobility Inc. positions itself as a premium provider of UAM services, focusing on speed, convenience, and customer experience. Its competitive advantage lies in its established brand, operational expertise, and technology platform.
Total Addressable Market (TAM)
The total addressable market for UAM is estimated to be in the tens of billions of dollars within the next decade. Blade is positioning itself to capture a significant share of this market by focusing on key routes and partnerships.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Established operational infrastructure
- Proprietary technology platform
- Strategic partnerships with aviation operators
- Leadership in MediMobility
Weaknesses
- High operating costs
- Reliance on regulatory approvals
- Limited geographic presence
- Dependence on helicopter availability
- Path to profitability is still unclear
Opportunities
- Expansion into new geographic markets
- Adoption of electric vertical takeoff and landing (eVTOL) aircraft
- Partnerships with airlines and travel agencies
- Growth in medical transportation demand
- Technological advancement lowering operating costs
Threats
- Economic downturn affecting discretionary spending
- Competition from new UAM providers
- Regulatory delays and restrictions
- Safety concerns and public perception
- Fluctuations in fuel prices
Competitors and Market Share
Key Competitors
- JOBY
- EH
- ACHR
Competitive Landscape
Blade has a first-mover advantage and strong brand, but faces competition from other UAM providers and traditional transportation services. The company's success depends on its ability to execute its growth strategy and manage its operating costs.
Major Acquisitions
Trinity Air Medical
- Year: 2021
- Acquisition Price (USD millions): 23
- Strategic Rationale: Expanded Blade's MediMobility business with fixed-wing organ transport capabilities.
Growth Trajectory and Initiatives
Historical Growth: Blade has experienced rapid revenue growth in recent years, driven by increasing demand for its services.
Future Projections: Analysts expect continued revenue growth, driven by expansion into new markets and the adoption of eVTOL aircraft. Profitability is expected to improve over time.
Recent Initiatives: Recent initiatives include expanding MediMobility services, exploring partnerships with eVTOL manufacturers, and developing its international presence.
Summary
Blade Air Mobility is pioneering urban air mobility with significant revenue growth, particularly in organ transport. However, high operating costs and a reliance on regulatory approvals present challenges. Successful expansion and eventual profitability are crucial for its long-term success. The adoption of eVTOL aircraft and strategic partnerships are key to its future trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Investor Presentations, Analyst Reports, Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and based on available information. Actual financial performance may differ from projections.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Blade Air Mobility Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-11-05 | Co- CEO, General Counsel & Corporate Secretary Ms. Melissa M. Tomkiel J.D. | ||
Sector Industrials | Industry Airports & Air Services | Full time employees 310 | Website https://www.blade.com |
Full time employees 310 | Website https://www.blade.com |
Blade Air Mobility, Inc. provides air transportation and logistics services for hospitals in the United States and internationally. The company operates in Passenger and Medical segments. It operates helicopter and amphibious seaplane flights in the United States and Europe; offers non-medical jet charter services; and transports human organs for transplant and/or the medical teams, as well as offers donor logistics coordination and support services. The company was founded in 2014 and is headquartered in New York, New York.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.